| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7682628 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Feb, 2025
(9 months from now) | |
| US8252809 | PURDUE PHARMA | Compositions for treating insomnia |
Feb, 2025
(9 months from now) | |
| US7658945 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Apr, 2027
(2 years from now) | |
| US8242131 | PURDUE PHARMA | Methods of treating middle-of-the-night insomnia |
Aug, 2029
(5 years from now) | |
Intermezzo is owned by Purdue Pharma.
Intermezzo contains Zolpidem Tartrate.
Intermezzo has a total of 4 drug patents out of which 0 drug patents have expired.
Intermezzo was authorised for market use on 23 November, 2011.
Intermezzo is available in tablet;sublingual dosage forms.
Intermezzo can be used as method for treating insomnia, method of treating middle-of-the-night insomnia.
The generics of Intermezzo are possible to be released after 20 August, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2014 |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia; Method of treating middle-of-the-night insomnia
Dosage: TABLET;SUBLINGUAL
INTERMEZZO family patents
